Exelixis, Inc. is a US-based pharmaceutical company specializing in developing innovative cancer treatments. With an ESG risk rating score of 22.5, it is considered to have a medium risk profile. Exelixis is known for its lead molecule cabozantinib, which is used to treat metastatic medullary thyroid cancer, kidney, and liver cancer. In partnership with Roche, they have also introduced Cotellic for melanoma treatment.